2013
Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)?
Hafeez F, Neboori HJ, Harigopal M, Wu H, Haffty BG, Yang Q, Schiff D, Moran MS. Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)? International Journal Of Radiation Oncology • Biology • Physics 2013, 87: 344-348. PMID: 23910708, DOI: 10.1016/j.ijrobp.2013.05.052.Peer-Reviewed Original ResearchConceptsBreast conservation therapyEarly-stage breast cancer patientsHuman epidermal growth factor receptor 2Recurrence-free survivalBreast cancer patientsKi-67 expressionKi-67Clinicopathologic featuresConservation therapyCancer patientsIndependent associationLocoregional recurrence-free survivalDistant metastasis-free survivalLocal relapse-free survivalEpidermal growth factor receptor 2Univariate/multivariate analysisPrognostic clinicopathologic featuresCause-specific survivalHormone receptor statusGrowth factor receptor 2Metastasis-free survivalRelapse-free survivalKi-67 overexpressionSignificant independent associationKi-67 staining
2007
Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population‐based analysis
Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA, Lissowska J, Peplonska B, Szeszenia‐Dąbrowska N, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Kalaylioglu Z, Harigopal M, Charrette L, Falk RT, Richesson D, Anderson WF, Hewitt SM, García‐Closas M. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population‐based analysis. International Journal Of Cancer 2007, 121: 1079-1085. PMID: 17487843, DOI: 10.1002/ijc.22812.Peer-Reviewed Original ResearchConceptsBody mass indexPostmenopausal womenEtiologic factorsHER2 levelsPremenopausal womenOdds ratioER alphaBreast cancer hormone receptor statusPopulation-based case-control studyBreast Cancer Hormone ReceptorsHormone receptor statusCase-control studyPopulation-based analysisPathologic characteristicsPR statusReceptor statusMass indexER betaClinical recordsMarker levelsHER2 expressionLarge tumorsBreast cancerReceptor levelsTumor features